In this article, we will take a look at some of the best AI driven biotech stocks that are currently offering attractive upside potential. On June 4, CNBC reported that global biopharma mergers and acquisitions are on course for their strongest year since before the pandemic. This trend is primarily driven by looming patent expirations, improving public market conditions, and pharmaceutical companies’ efforts to strengthen their product pipelines. According to PitchBook data, biotech and pharmaceutical deal-making totaled $106 billion across 201 transactions through the reporting period in 2026, putting the industry on track to exceed $250 billion in deal value for the year if the current pace continues.
Strategic acquisitions and corporate add-ons continue to dominate activity, with drug discovery accounting for a significant share of deal flow. The average deal value increased from $365 million in 2025 to over $527 million in 2026. As pharmaceutical companies look for assets that are easy to incorporate into their current portfolios, acquisitions in the $1 billion to $5 billion range have remained particularly active.
Western pharmaceutical companies have looked to China for innovation, where there is still significant interest in acquiring biotech assets. The industry has also benefited from improved investor optimism, as evidenced by the biotech index XBI’s 50% increase over the previous 12 months and several successful IPOs, signaling a more active market environment. With that background, let’s explore our 10 Best AI Driven Biotech Stocks to Invest In.
everything possible/Shutterstock.com
Our Methodology
To identify relevant stocks for this article, we screened U.S.-listed biotech companies that are heavily leveraging artificial intelligence capabilities. Our search includes companies with market capitalizations above $2 billion and offering at least 60% upside potential, according to consensus, as of the June 5 close. Finally, we selected 10 stocks with the highest upside and ranked them in ascending order.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. Corcept Therapeutics Inc. (NASDAQ:CORT)
Corcept Therapeutics Inc. (NASDAQ:CORT) is one of the 10 best AI driven biotech stocks to invest in.
On June 8, Corcept Therapeutics Inc. revealed the latest data from Catalyst and Momentum trials during the American Diabetes Association’s 86th Scientific Sessions. The results show a crucial role of hypercortisolism in type 2 diabetes, which appears to be difficult to contain. Moreover, it also extends influence on resistant hypertension.
The data also indicated the potential of the cortisol modulation procedure. The company’s Chief Development Officer, Bill Guyer, expanded on the data by emphasizing that hypercortisolism seems to be a major driver of cardiometabolic conditions. He stated:
“Data consistently show that hypercortisolism is an underlying driver of treatment resistant cardiometabolic disease, including in patients receiving best-in-class therapies like GLP-1s. Data from CATALYST demonstrate that treatment with a cortisol modulator, such as Korlym, can be synergistic with GLP-1s or tirzepatide to help patients better control type 2 diabetes. It is our hope that this new research will lead to increased screening for hypercortisolism and improved treatment.”
Back on May 28, Canaccord Genuity increased its target price for Corcept Therapeutics Inc. from $110 to $135, which represents an adjusted upside potential of almost 77%. The firm reiterated a Buy rating on the stock.
Genuity attributed the revision to the company’s surprise announcement, where they intend to resubmit the NDA relating to relacorilant, which will be utilized to cure patients with hypercortisolism.
Corcept Therapeutics Inc. is a commercial-stage pharmaceutical company that is involved in developing therapies for severe conditions. These include endocrinologic, oncologic, metabolic, and neurologic disorders. It is developing medicines that target hyperglycemia, hypercortisolism, prostate cancer, and amyotrophic lateral sclerosis.
9. Kymera Therapeutics Inc. (NASDAQ:KYMR)
Kymera Therapeutics Inc. (NASDAQ:KYMR) is one of the 10 best AI driven biotech stocks to invest in.
On June 8, Brookline Capital Markets increased the target price for Kymera Therapeutics from $91 to $97, resulting in a revised upside potential in excess of 30%. The firm also upheld its Buy rating on the stock amid the latest preclinical outcome related to KT-579. The data, presented at FOCUS and EULAR, exhibit similar or more enhanced activity relative to the approved clinical agents, and also show disease-altering characteristics across the lupus models.
Back in May, new preclinical findings for KT-579, a powerful and selective oral IRF5 degrader, were released by Kymera Therapeutics Inc.. The findings emphasized the drug’s potential to change inflammatory bowel disease (IBD). The results, which were demonstrated at Digestive Disease Week (DDW) 2026 in Chicago, show that targeted degradation of IRF5 can concurrently modulate multiple important inflammatory pathways that are involved in complex autoimmune diseases, such as pro-inflammatory cytokines, autoantibody responses, and Type I interferons.
Despite current treatments, numerous individuals with chronic inflammatory illnesses still have insufficient disease control, according to Kymera. KT-579 is designed to offer a convenient oral therapy capable of addressing multiple disease-driving mechanisms at once. Prior preclinical research in models of rheumatoid arthritis and lupus revealed activity that was either on par with or better than the existing standards of care.
KT-579 decreased the severity of the disease, stopped weight loss, preserved colon health, inhibited important inflammatory cytokines, and enhanced tissue pathology in an IBD TNBS model. Extensive normalization of inflammatory and fibrosis-related pathways was revealed by transcriptomic studies. Data from a Phase 1 healthy volunteer study evaluating KT-579 is anticipated in the latter half of 2026.
Kymera Therapeutics Inc. is a biopharmaceutical company that discovers and develops small-molecule therapeutics to destroy the specific proteins that cause disease in the human body. It is developing KT-579, KT-485/SAR447971, cyclin-dependent kinase 2 (CDK2) and KT-621. The company is also working on the IRAK4 program, which is in Phase II clinical trial.
8. Relay Therapeutics Inc. (NASDAQ:RLAY)
Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the 10 best AI driven biotech stocks to invest in.
On May 20, JonesResearch updated its coverage on Relay Therapeutics Inc. after reviewing encouraging initial data for its drug, zovegalisib. The firm upgraded its rating on the stock from a Hold to a Buy. The firm also increased its price target from $18 to $20, based on the positive early results for zovegalisib in treating vascular anomalies. This results in a revised upside potential of almost 48%.
The firm said that the available data show that the treatment is demonstrating clear efficacy. Consequently, the firm raised its estimated probability of commercial success for the drug in treating vascular malformations, doubling the metric from 20% to 40%.
On May 19, the preliminary clinical outcome for Relay Therapeutics Inc.’s (NASDAQ:RLAY) drug zovegalisib showed a 60% response rate at 12 weeks for PIK3CA-driven vascular anomalies. It also worked well in patients who had already failed multiple past treatments.
Because of these results, Raymond James told investors the drug could be way safer and more effective than what’s out there now, offering a massive commercial opportunity. As a result, the firm reiterated its Strong Buy rating on the stock and raised the price target from $23 to $26.
Relay Therapeutics Inc. operates as a clinical-stage precision medicines company. The company’s lead product candidates include RLY-8161, lirafugratinib (RLY-4008), RLY-2608, and aGal chaperone. It has strategic alliances with entities such as Elevar Therapeutics, Pfizer, and D. E. Shaw Research for the development of several therapeutic drugs.
7. Erasca Inc. (NASDAQ:ERAS)
Erasca Inc. (NASDAQ:ERAS) is one of the 10 best AI driven biotech stocks to invest in.
As of the close of play on June 5, consensus sentiment for Erasca Inc. was strongly bullish. Based on a 1-year target price of $21, the stock offers an upside potential of more than 75% at the current level. It received Buy ratings from 8 of the 10 analysts who provided coverage, while 2 analysts gave Hold calls.
On June 4, early clinical trial results for Erasca Inc. pan-RAS treatment ERAS-0015 indicate legitimacy, and medical experts in the field have provided highly positive feedback on its performance. Because of this, the primary discussion among investors is no longer about whether the drug actually functions, but rather how commercially effective it can be.
Bank of America Securities noted that the stock’s current price gives a much fairer picture of the underlying risks involved. Consequently, the firm upgraded the stock from Underperform to a Neutral rating. In the process, it also raised the price target from $9 to $16, leading to an adjusted upside of almost 34%.
Back on May 12, Mizuho cut down its target price for Erasca Inc. from $28 to $26, which still yields more than 117% upside potential for investors. The firm also maintained its Outperform rating for the stock.
Erasca Inc. is a clinical-stage precision oncology company that focuses on developing and commercializing therapies for RAS/MAPK pathway-driven cancers. The product pipeline includes ERAS-0015, ERAS-4001, and ERAS-12. It has established licensing agreements with multiple pharmaceutical partners for the development of additional therapeutic compounds. These include naporafenib, ERAS-601, and ERAS-007.
6. Denali Therapeutics Inc. (NASDAQ:DNLI)
Denali Therapeutics Inc. (NASDAQ:DNLI) is one of the 10 best AI driven biotech stocks to invest in.
On May 22, Denali Therapeutics Inc. halted its joint work with Biogen Inc. (NASDAQ:BIIB), around the development of BIIB122 for idiopathic Parkinson’s disease. The decision came after topline results from the Phase 2b LUMA trial showed that the investigational small molecule inhibitor did not perform better than a placebo at slowing down symptoms, missing both primary and secondary clinical measures.
Even though the molecule did not achieve its main clinical goals, lab tests showed it hit its expected biological targets. It achieved over 90% kinase inhibition of peripheral LRRK2, alongside an estimated 30% biomarker reduction in spinal fluid, while maintaining a safe profile.
Looking ahead, Denali plans to independently conduct the global Phase 2a BEACON trial to test the drug in patients who carry a specific genetic mutation, with initial results expected in the first half of 2027.
On May 22, Morgan Stanley adjusted its view of Denali Therapeutics Inc.. The firm kept an Overweight rating on the stock but lowered its price target from $40 to $35. This update came after the Phase 2b LUMA study missed its primary and secondary endpoints, which caused the cancellation of the BIIB122 drug program.
The firm noted that the stock valuation will now depend on other assets in the company pipeline and the validation of their overall platform. Despite this, Morgan Stanley’s projected price target leads to an adjusted upside potential of almost 80% at the prevailing level.
Denali Therapeutics Inc. is a biotechnology company that utilizes proprietary technology to address neurodegenerative diseases. Through their TransportVehicle™ platform and by leveraging the power of biotherapeutics, they develop medicines for some very serious conditions, including lysosomal storage.
5. IDEAYA Biosciences Inc. (NASDAQ:IDYA)
IDEAYA Biosciences Inc. (NASDAQ:IDYA) is one of the 10 best AI driven biotech stocks to invest in.
On June 3, in order to study the safety and efficacy of IDE892 in conjunction with Roche’s pan-RAS inhibitor, RG6505, in patients with MTAP-deleted pancreatic ductal adenocarcinoma, Ideaya Biosciences Inc. and Roche (RHHBY) formed a clinical partnership. Roche will provide RG6505 for the investigation, and Ideaya will oversee and finance the combination experiment.
Copyright: mikkolem / 123RF Stock Photo
Whether used separately or in combination, both firms will keep all commercial licenses to their individual treatments. Ideaya and Roche will share governance of the cooperation. Subject to both firms’ approval, the agreement also allows for the evaluation of a three-drug combination that comprises IDE892, RG6505, and IDE397, Ideaya’s Phase 2 MAT2A inhibitor.
On June 1, IDEAYA Biosciences shared its full Phase 2/3 data for its skin cancer drug trial at the ASCO meeting. The global study evaluated 313 patients, and the big news is that their new drug combination cut the risk of the disease getting worse by 58%.
Patients on the new treatment went 6.9 months without the disease progressing, compared to only 3.1 months for patients on standard treatments. The technical data also showed a major increase in response rates above 37% versus 5.8%, alongside a 73.3% disease control rate compared to 31.1% for the control group.
The company is already working on its official FDA application under a real-time review program, and they expect to finish submitting everything in the second half of 2026. The drug was mostly safe, and very few people stopped taking it. Final survival data is not ready yet, but the early trends look promising.
IDEAYA Biosciences Inc. is a precision medicine oncology company, offering antibody drug inhibitors such as IDE161, IDE705, IDE397, IDE892, and more. The company also offers Darovasertib in multiple clinical trials and provides preclinical research programs focused on pharmacological inhibition. These include the INQUIRE chemical library and the HARMONY machine-learning engines.
4. Mineralys Therapeutics Inc. (NASDAQ:MLYS)
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 10 best AI driven biotech stocks to invest in.
On June 3, Mineralys Therapeutics shared a major update regarding its blood pressure drug, lorundrostat. The company is repurchasing its potential royalty payments from Tanabe Pharma Corporation. Mineralys is paying $200 million upfront and up to $100 million later based on commercial milestones.
This moves their total possible future milestone payments to Tanabe up to $265 million, which includes the $100 million in new milestones and $165 million in old milestones, with up to $10 million tied to a second indication. Tanabe will also hand over the intellectual property rights for the drug.
To fund this, Mineralys initiated a $500 million agreement for a senior secured term loan with Pharmakon Advisors that matures in June 2031. They are getting $100 million of that debt immediately at closing, and the rest will come in three separate tranches. The interest rate is based on SOFR with a 3.25% floor, plus a 5.50% annual margin. On top of the loan, Mineralys also priced a separate stock offering to sell about $150 million of its common stock to help cover the upfront costs.
Mineralys Therapeutics Inc. engages in the development of therapeutics that target illnesses caused by dysregulated aldosterone. It is working on the development of lorundrostat, an aldosterone synthase inhibitor for cardiorenal conditions. These include chronic kidney disease, hypertension, and obstructive sleep apnea.
3. Dyne Therapeutics Inc. (NASDAQ:DYN)
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 best AI driven biotech stocks to invest in.
On June 3, enrollment for the Phase 1/2 ACHIEVE trial’s registrational expansion cohort, which evaluates z-basivarsen (DYNE-101) in individuals with myotonic dystrophy type 1 (DM1), has concluded, according to a statement from Dyne Therapeutics Inc.. The business sees this as a significant step in developing what it thinks may be a best-in-class medication meant to address the disease’s wide range of symptoms.
According to Chief Medical Officer Doug Kerr, data from the cohort is anticipated in the first quarter of the next year and may show significant improvements in myotonia coupled with favorable trends in important functional metrics. Kerr stated:
“Completing enrollment in the registrational expansion cohort of ACHIEVE is a critical milestone as we advance a potentially best-in-class therapy designed to address the multi-system nature of DM1. With data from this cohort expected in the first quarter of next year, we believe we are well positioned to show a significant improvement in myotonia and trends on important functional outcomes to support a potential submission for U.S. Accelerated Approval. We expect that the strong interest we have seen in z-basivarsen will support enrollment in the ongoing confirmatory Phase 3 HARMONIA trial.”
Dyne Therapeutics Inc. is a biotechnology company that formulates life-transforming targeted therapeutics for individuals with genetically driven neuromuscular diseases. It uses its FORCE platform to identify the root cause of a condition and currently has a strong pipeline of clinical and preclinical programs.
2. Praxis Precision Medicines Inc. (NASDAQ:PRAX)
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 best AI driven biotech stocks to invest in.
On June 2, BTIG reduced the price target on Praxis Precision Medicines Inc. from $843 to $810. The firm maintained a Buy rating on the stock, informing investors that although the company’s Phase 2/3 POWER1 trial of vormatrigine resulted in a revenue loss, there is still hope for a recovery for the program.
Approximately 90% of patients in the vormatrigine-arm moved into the open-label extension and stayed there; the 50% rate of response secondary indicator met the criteria, seizure diminution was more noticeable in the remainder of the study on the increased 30 mg dose, and detrimental event-related withdrawals had been less than 10%.
Back on May 13, Truist Financial increased the price target from $700 to $715 while assuming a Buy rating for Praxis Precision Medicines Inc.. Truist highlighted that over the next six to eight months, the company is well-positioned for many value-inflecting events.
This positive outlook is supported by the strong late-stage pipeline of de-risked assets. The firm also pointed out that Praxis’s late-stage portfolio may grow into a franchise worth billions of dollars.
Praxis Precision Medicines Inc. is involved in developing therapies to cure disorders related to the central nervous system, which are characterized by neuronal excitation-inhibition imbalance. These disorders include epilepsy, movement disorders, and depression. The company utilizes its proprietary platforms like Cerebrum and Solidus to target such imbalances.
1. Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX)
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 best AI driven biotech stocks to invest in.
As of the June 5 close, Crinetics Pharmaceuticals Inc. had a strongly bullish consensus sentiment. Based on a 1-year target price of $88.14, the stock offers an upside potential of more than 167%% at the prevailing level. It received Buy ratings from all 8 analysts who provided coverage.
On June 2, Crinetics Pharmaceuticals Inc. revealed that the company will be sharing data across 6 different presentations during the Endocrine Society’s Annual Meeting, ENDO 2026, in mid-June. Three of those presentations will be around PALSONIFY, which will incorporate data on long-term safety and efficacy from the open-label extension (OLE) studies, i.e., PATHFNDR-1 and PATHFNDR-2.
Besides that, there will be three presentations around the company’s atumelnant clinical development program. The company will share data from the Phase 2 study on congenital adrenal hyperplasia (CAH), along with Phase 1b/2a results for ACTH-dependent Cushing’s syndrome.
Back on May 15, Gavin Clark-Gartner from Evercore ISI reduced his target price for Crinetics Pharmaceuticals Inc. from $89 to $88, resulting in an adjusted upside potential in excess of 167%. The firm maintained its Outperform rating on the stock.
Crinetics Pharmaceuticals Inc. is engaged in developing and marketing innovative treatments for rare endocrine diseases and endocrine-related tumors. The company offers a range of therapies that are currently in different stages of clinical trials. These include Paltusotine, Atumelnant, CRN09682, oral GLP-1, and GIP nonpeptide.
